Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Staphylococcus aureus | Quinolone resistance protein norA | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Leishmania braziliensis | hypothetical protein, conserved | Get druggable targets OG5_134723 | All targets in OG5_134723 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | DNA gyrase subunit B, putative | 0.269 | 1 | 1 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.1555 | 0.5455 | 1 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.269 | 1 | 1 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0629 | 0.1747 | 0.3202 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.269 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0436 | 0.0977 | 0.379 |
Schistosoma mansoni | glycogen phosphorylase | 0.0362 | 0.0677 | 0.2628 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0629 | 0.1747 | 0.6778 |
Mycobacterium leprae | Probable DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) | 0.0926 | 0.2938 | 1 |
Echinococcus granulosus | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Brugia malayi | Probable DNA topoisomerase II | 0.0629 | 0.1747 | 0.6778 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0629 | 0.1747 | 0.6778 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0629 | 0.1747 | 0.6778 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0836 | 0.2577 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.1555 | 0.5455 | 1 |
Echinococcus multilocularis | Glycosyl transferase, family 35 | 0.0836 | 0.2577 | 1 |
Leishmania major | DNA topoisomerase ii | 0.0436 | 0.0977 | 0.1791 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0836 | 0.2577 | 1 |
Loa Loa (eye worm) | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Schistosoma mansoni | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0629 | 0.1747 | 0.6778 |
Trypanosoma brucei | DNA topoisomerase ii | 0.1555 | 0.5455 | 1 |
Plasmodium falciparum | DNA gyrase subunit B | 0.269 | 1 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0629 | 0.1747 | 0.6778 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.269 | 1 | 1 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.1764 | 0.6292 | 0.6292 |
Chlamydia trachomatis | glycogen phosphorylase | 0.0836 | 0.2577 | 0.2577 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.0629 | 0.1747 | 0.6778 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0629 | 0.1747 | 0.1747 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0362 | 0.0677 | 0.2628 |
Echinococcus granulosus | Glycosyl transferase family 35 | 0.0836 | 0.2577 | 1 |
Brugia malayi | carbohydrate phosphorylase | 0.0836 | 0.2577 | 1 |
Entamoeba histolytica | glycogenphosphorylase, putative | 0.0362 | 0.0677 | 0.2628 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0629 | 0.1747 | 0.6778 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0629 | 0.1747 | 0.6778 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.1555 | 0.5455 | 1 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0436 | 0.0977 | 0.1791 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0362 | 0.0677 | 0.2628 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0629 | 0.1747 | 0.6778 |
Mycobacterium ulcerans | glycogen phosphorylase GlgP | 0.0362 | 0.0677 | 0.0677 |
Schistosoma mansoni | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0629 | 0.1747 | 0.6778 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.269 | 1 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0544 | 0.1409 | 0.5467 |
Echinococcus granulosus | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.1555 | 0.5455 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0436 | 0.0977 | 0.1791 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0629 | 0.1747 | 0.1747 |
Loa Loa (eye worm) | hypothetical protein | 0.0436 | 0.0977 | 0.379 |
Onchocerca volvulus | Glycogen phosphorylase homolog | 0.0836 | 0.2577 | 1 |
Schistosoma mansoni | DNA topoisomerase II | 0.0629 | 0.1747 | 0.6778 |
Giardia lamblia | Glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0436 | 0.0977 | 0.1791 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0836 | 0.2577 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0436 | 0.0977 | 0.1791 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0836 | 0.2577 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 8.3 uM | Inhibition of NorA in Staphylococcus aureus 1199B harboring grlA A116E mutant assessed as inhibition of ethidium bromide efflux measured for 5 mins by fluorometric analysis | ChEMBL. | 23710549 |
Inhibition (binding) | = 93.4 % | Inhibition of NorA in Staphylococcus aureus 1199B harboring grlA A116E mutant assessed as inhibition of ethidium bromide efflux at 50 uM measured for 5 mins by fluorometric analysis relative to control | ChEMBL. | 23710549 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.